Study of Magrolimab (Hu5F9-G4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer
Ontology highlight
ABSTRACT: The primary objectives of this study are: (Phase 1b) to investigate the safety and tolerability and to determine the recommended Phase 2 dose (RP2D) for magrolimab in combination with cetuximab; and (Phase 2) to evaluate overall response rate (ORR) of magrolimab in combination with cetuximab in participants with Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) mutant and KRAS wild-type colorectal cancer (CRC).
DISEASE(S): Solid Tumor,Colorectal Cancer,Colorectal Neoplasms
PROVIDER: 2229069 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA